Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049578 | 0.86 | TBXAS1 (0.49) | NPC1MAPTRAB9ATBXAS1ADORA2A | |
| SCHEMBL4053223 | 0.86 | TBXAS1 (0.51) | TBXAS1ADORA2AADORA1 | |
| SCHEMBL4057614 | 0.84 | TBXAS1 (0.44) | MAPTTBXAS1ADORA2AADORA1 | |
| SCHEMBL4050532 | 0.83 | TBXAS1 (0.41) | TBXAS1ADORA2AADORA1GRM5 | |
| SCHEMBL4058144 | 0.82 | ALDH1A1 (0.47) | NPC1RAB9ATBXAS1ADORA2AADORA1 | |
| SCHEMBL4056464 | 0.81 | TBXAS1 (0.43) | TBXAS1ADORA2AADORA1 | |
| SCHEMBL4051805 | 0.81 | PDE4B (0.46) | TBXAS1ADORA2AADORA1 | |
| SCHEMBL4053338 | 0.80 | TSHR (0.59) | MAPTADORA2AADORA1 | |
| SCHEMBL5750630 | 0.78 | TBXAS1 (0.46) | TBXAS1ADORA2AADORA1 | |
| SCHEMBL2827023 | 0.77 | AURKA (0.47) | NPC1RAB9ASMN1; SMN2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511038-B2 | Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-31 | — | — | US | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | PDE10A 36/4885NPC1 3779/4885MAPT 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.